X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs WYETH LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA WYETH LTD GSK PHARMA/
WYETH LTD
 
P/E (TTM) x 60.0 27.7 216.3% View Chart
P/BV x 11.2 5.3 209.5% View Chart
Dividend Yield % 2.6 1.3 201.9%  

Financials

 GSK PHARMA   WYETH LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
WYETH LTD
Mar-13
GSK PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs2,7601,044 264.3%   
Low Rs2,040818 249.4%   
Sales per share (Unadj.) Rs339.0298.6 113.5%  
Earnings per share (Unadj.) Rs41.457.2 72.4%  
Cash flow per share (Unadj.) Rs45.958.4 78.6%  
Dividends per share (Unadj.) Rs35.0017.00 205.9%  
Dividend yield (eoy) %1.51.8 79.9%  
Book value per share (Unadj.) Rs242.9249.5 97.4%  
Shares outstanding (eoy) m84.7022.72 372.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.13.1 227.0%   
Avg P/E ratio x57.916.3 356.2%  
P/CF ratio (eoy) x52.315.9 328.0%  
Price / Book Value ratio x9.93.7 264.7%  
Dividend payout %84.529.7 284.5%   
Avg Mkt Cap Rs m203,28021,157 960.8%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m5,234400 1,308.5%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m28,7156,783 423.3%  
Other income Rs m545353 154.7%   
Total revenues Rs m29,2607,136 410.0%   
Gross profit Rs m5,0591,617 312.8%  
Depreciation Rs m38027 1,428.6%   
Interest Rs m26 36.4%   
Profit before tax Rs m5,2221,938 269.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m178-5 -3,490.2%   
Tax Rs m1,892632 299.3%   
Profit after tax Rs m3,5081,301 269.7%  
Gross profit margin %17.623.8 73.9%  
Effective tax rate %36.232.6 111.1%   
Net profit margin %12.219.2 63.7%  
BALANCE SHEET DATA
Current assets Rs m21,8156,984 312.4%   
Current liabilities Rs m15,9992,056 778.2%   
Net working cap to sales %20.372.6 27.9%  
Current ratio x1.43.4 40.1%  
Inventory Days Days6499 64.1%  
Debtors Days Days1924 78.1%  
Net fixed assets Rs m12,475244 5,106.4%   
Share capital Rs m847227 372.8%   
"Free" reserves Rs m19,7265,441 362.6%   
Net worth Rs m20,5735,668 363.0%   
Long term debt Rs m625 24.0%   
Total assets Rs m39,4757,901 499.6%  
Interest coverage x2,612.0353.3 739.3%   
Debt to equity ratio x00 6.6%  
Sales to assets ratio x0.70.9 84.7%   
Return on assets %8.916.5 53.8%  
Return on equity %17.122.9 74.3%  
Return on capital %26.234.0 77.1%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m56415 3,710.5%   
Fx outflow Rs m7,4292,677 277.5%   
Net fx Rs m-6,865-2,662 257.9%   
CASH FLOW
From Operations Rs m4,728923 512.1%  
From Investments Rs m-1,042317 -328.8%  
From Financial Activity Rs m-3,066-481 637.5%  
Net Cashflow Rs m620759 81.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.1 99.2%  
Indian inst/Mut Fund % 10.2 11.3 90.3%  
FIIs % 23.8 7.2 330.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 30.4 50.7%  
Shareholders   102,036 21,978 464.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Hero MotoCorp & Sun Pharma Top Gainers(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.3% while the Hang Seng is up 0.2%.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 15, 2018 11:37 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS